Answers are grounded in this paper and cite their sources.
Skin rejuvenating fillers based on regenerated silk fibroin (SF) hydrogel exhibit desirable long-lasting filling effects. However, the rapid loss of mechanical strength severely limits the shelf-life of the corresponding products, posing challenges to their storage, transportation, and commercialization. To address this issue, SF solution was mixed with hydrophilic hyaluronic acid (HA) and cross-linked with butanediol diglycidyl ether (BDDE), a commercial agent used in the biomedical field, to prepare hydrogels. Experimental data indicated that an appropriate ratio of HA significantly improved the mechanical stability of the SF hydrogel for at least three months. In vitro cell assays further demonstrated that SF/HA hydrogels promoted human umbilical vein endothelial cell (HUVEC) migration and tube formation, as well as fibroblast migration, indicating pro-angiogenic and pro-regenerative bioactivities. After being fabricated into microparticles, SF/HA hydrogels were subcutaneously injected as skin fillers. The injected microparticles gradually degraded over the following 6 months. Notably, these microparticles facilitate angiogenesis, recruit fibroblasts, and promote the generation of type Ⅰ and type Ⅲ collagen, thereby facilitating autologous skin filling. Together, these data indicate that the BDDE cross-linked SF/HA hydrogels possess excellent long-term mechanical stability, biodegradability, and bioactivity, exhibiting great potential for biomedical and aesthetic medicine.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: